Suscribirse

Anemia and Heart Failure: A Community Study - 20/08/11

Doi : 10.1016/j.amjmed.2008.03.039 
Shannon M. Dunlay, MD a, Susan A. Weston, MS b, Margaret M. Redfield, MD a, Jill M. Killian, BS b, Véronique L. Roger, MD, MPH a, b,
a Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minn 
b Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minn. 

Requests for reprints should be addressed to Véronique L. Roger, MD, MPH, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Abstract

Purpose

Anemia is an important comorbidity in heart failure and has been associated with increased mortality. The goals of this study were to define the prevalence of anemia in a community population with heart failure, examine trends in prevalence over time, and evaluate the role of anemia in patients with heart failure with preserved and reduced ejection fraction.

Methods

Two cohorts of Olmsted County residents with heart failure were examined. The retrospective cohort included incident heart failure cases from 1979 to 2002 (n=1063). The prospective cohort included active heart failure cases from 2003 to 2006 (n=677). Clinical characteristics were collected. Anemia was defined by World Health Organization criteria.

Results

The prevalence of anemia was 40% in the retrospective cohort and 53% in the prospective cohort. Anemia prevalence increased by an estimated 16% between 1979 and 2002 (P=.008) and was higher in those with preserved (≥50%) versus reduced (<50%) ejection fraction (58% vs 48%, respectively, P<.001) from 2003 to 2006. Anemia was associated with a large increase in the risk of death (P<.001 both cohorts). The relationship between mortality and hemoglobin followed a J-shaped curve, with increased mortality with hemoglobin levels less than 14 mg/dL and greater than 16 mg/dL. In the prospective cohort, after adjustment for clinical characteristics, the hazard ratios (95% confidence interval) for death were 3.07 (1.26-6.82) in those with a hemoglobin level of 16 mg/dL or more and 2.39 (1.37-4.27) in those with a hemoglobin level less than 10 mg/dL, using hemoglobin 14 to 16 mg/dL as the referent.

Conclusion

In the community, half of patients with heart failure are anemic, and the prevalence of anemia has increased over time. Anemia is more prevalent in heart failure with preserved ejection fraction and is associated with a large increase in mortality.

El texto completo de este artículo está disponible en PDF.

Keywords : Anemia, Epidemiology, Heart failure, Hemoglobin, Mortality, Prevalence


Esquema


 This study was supported by grants from the National Institute of Health (RO1 HL 59205, RO1 HL 72435) and by an American Heart Association Postdoctoral Greater Midwest Fellowship Award to Dr Dunlay. Dr Roger is an Established Investigator of the American Heart Association.


© 2008  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 121 - N° 8

P. 726-732 - août 2008 Regresar al número
Artículo precedente Artículo precedente
  • 64-Slice CT for Diagnosis of Coronary Artery Disease: A Systematic Review
  • Paul D. Stein, Abdo Y. Yaekoub, Fadi Matta, H. Dirk Sostman
| Artículo siguiente Artículo siguiente
  • Hyperkalemia Caused by Penicillin
  • A. Thiele, Habib U. Rehman

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.